L5: Adrenergic agonists; sympathomimetics

Post on 23-Jan-2015

1.227 views 2 download

description

 

Transcript of L5: Adrenergic agonists; sympathomimetics

April 10, 2023 1

Adrenergic agonists

Sympathomimetics drugs

Pharmacology I/ Lecture 5Dr. Hiwa K. Saaed, HD, M.Sc, Ph.D

April 10, 2023 2

agents that act on pathways mediated by the endogenous catecholamines (CAO); 1. norepinephrine2. epinephrine.

NEP & EP are modulate the Rate and force of contraction of heart. Resistance (constriction and dilation) of

blood vessels and bronchioles. Release of insulin, breakdown of fat (lipolysis).

Adrenergic agonists

April 10, 2023 3

synthesis, storage, release, binding removal (reuptake) of the neurotransmitter

They are frontline therapies for hypertension, depression, shock, asthma, angina & etc.

drugs target:

April 10, 2023 4

Tyrosine hydroxylase can be inhibited by methyl-p-tyrosine.

MAO: inhibitors of MAO (e.g., phenelzine, tranylcypromine)

The mobile pool; many indirect-acting sympathomimetics (e.g., amphetamine, ephedrine, tyramine) can displace NE from the mobile pool

Uptake: some indirect-acting sympathomimetics (cocaine, TCA).

Drug Targets

April 10, 2023 5

Prejunctional α-receptors: (e.g., clonidine, alpha methyldopa) cause inhibition of NE release.

Granular uptake of NE: blocker of granular uptake of NE (e.g., reserpine) .

NE release from granules: blockers (e.g., guanethidine).

Postjunctional receptors: postjunctional receptors can be activated or blocked.

Drug Targets

Classification

April 10, 2023 6

divided into subgroups on the basis of their

Spectrum of action: α, β, or dopamine

receptor affinity Mode of action: direct, indirect or

both

April 10, 2023 7

Adrenergic agonists Direct acting:I. α agonists: • Non selective, • α1-selective, • α2-selective II. β agonists: • Non selective, • β1-selective, • Β2-selective

April 10, 2023 8

Indirect acting ↑ CAO in the synapse:

1. Releaser: Amphetamine, tyramine

Potentiate by MAOI, COMT blocker. Why?

2. Reuptake inhibitor: Cocaine, TCA Mixed: Ephedrine, metaraminol

Adrenergic agonists

April 10, 2023 9

Removal of NE may:

Diffuse out and enter the general circulation. Be metabolized by COMT in the synaptic Be recaptured by an uptake systems into the

neuron

April 10, 2023 10

Adrenoceptors

Selective for NE & EP. dopamine can also activate some adrenoceptors at

very high ‘supraphysiologic’ concentrations.

Divided into two main classes: α & β adrenoceptors All are members of GPCR superfamily.

April 10, 2023 11

α-receptors: EP≥NE>>Isoproterenol

β-receptors: Isop>EP>NE

April 10, 2023 12

April 10, 2023 13

based on their affinities for a agonists and blocking drugs, α-receptors are subdivided into two subgroups α1 & α2,

e.g., α1 receptors have a higher affinity for phenylephrine than do α2 receptors.

Conversely, clonidine selectively binds to α2 receptors and has less effect on α1 receptors.

α-adrenoceptors (α1 & α2)

April 10, 2023 14

α-receptors: α1 Are present on the postsynaptic membrane

α2 Located primarily on presynaptic nerve endings.

The stimulation of α2 receptors causes feedback inhibition of the ongoing release of NE;

α2 Located on other cells such as the β-cell of the pancreas control insulin output.

April 10, 2023 15

April 10, 2023 16

β-receptors:

Subdivided to β1, β2 and β3-receptors β1-receptors have ~equal affinities for both EP &

NE., β2-receptors have higher affinity for EP than for

NE. thus tissue with a predominance of β2-receptors

(vasculature of skeletal muscle) are particularly responsive to hormonal effects of circulating EP released by adrenal medulla.

April 10, 2023 17

β-receptors

Mechanism of action: binding of neurotransmitter at the β1 or β2-receptor→

result in activation of AC→↑cAMP concentrations within the cell.

April 10, 2023 18

Mechanisms of action of adrenergic receptors :

April 10, 2023 19

April 10, 2023 20

Desensitization of receptors:

Prolonged exposure to the CAO reduces the responsiveness of the receptors due to:

1. Sequestration of the receptors

2. Downregulation (destruction, or decreased synthesis)

3. An inability to couple to G-protein

April 10, 2023 21

A. Catecholamine properties:

High potency in activating α & β receptors Rapid inactivation by:

1. COMT postsynaptically, gut wall,

2. MAO intraneuronally, liver or gut

Thus,

CAO have only a brief duration of action when given parenterally, and are ineffective when administered orally because of inactivation.

Poor penetration into the CNS (polar)

April 10, 2023 22

B. Non Catecholamine properties :

phenylephrine, ephedrine, amphetamine Have longer t1/2 because they are not inactivated by

COMT, and they are poor substrate for MAO Increased lipid solubility permits the greater access to

the CNS

April 10, 2023 23

Major effects mediated by adrenoceptors

April 10, 2023 24

SITE OF ACTION

April 10, 2023 25

SITE OF ACTION